Please login to order a test.
Treatment of susceptible fungal infections in immunocompromized and immunocompetent patients including blastomycosis and histoplasmosis; indicated for aspergillosis and onychomycosis of the toenail and fingernail. It has been recommended that routine monitoring occur during the first week of therapy to ensure therapeutic levels are achieved for each individual and to continue monitoring if clinical presentations do not improve or decline.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Serum (preferred) or plasma
Red-top tube or lavender-top (EDTA) tube
Transfer separated serum or plasma to a plastic transport tube. Do not use a gel barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant.
Refrigerate. Stable for 14 days at room temperature, refrigerated, or frozen.
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|700282||Itraconazole, Serum/Plasma||10989-2||700283||Itraconazole, Serum/Plasma||ug/mL||10989-2|